Diseases /
Prostate Adenocarcinoma
Back to Diseases List
Associated Genetic Biomarkers
Overview
NCI Definition: An adenocarcinoma arising from the prostate gland. It is one of the most common malignant tumors afflicting men. The majority of adenocarcinomas arise in the peripheral zone and a minority occurs in the central or the transitional zone of the prostate gland. Grading of prostatic adenocarcinoma predicts disease progression and correlates with survival. Several grading systems have been proposed, of which the Gleason system is the most commonly used. Gleason sums of 2 to 4 represent well-differentiated disease, 5 to 7 moderately differentiated disease and 8 to 10 poorly differentiated disease. Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic adenocarcinoma. Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy. Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease. [1]
Prostate adenocarcinomas most frequently harbor alterations in TP53, TMPRSS2, ERG, PTEN, and AR [2].
TMPRSS2-ERG Fusion, TP53 Mutation, TP53 Missense, TP53 c.217-c.1178 Missense, and AR Amplification are the most common alterations in prostate adenocarcinoma [2].
Clinical Trials
There are 337 clinical trials for prostate adenocarcinoma, of which 306 are open and 31 are completed or closed. Of the trials that contain prostate adenocarcinoma as an inclusion criterion, 9 are early phase 1 (9 open), 52 are phase 1 (45 open), 47 are phase 1/phase 2 (42 open), 146 are phase 2 (131 open), 3 are phase 2/phase 3 (3 open), 39 are phase 3 (39 open), 3 are phase 4 (3 open), and 38 are no phase specified (34 open).
BRCA1, BRCA2, and ATM are the most frequent gene inclusion criteria for prostate adenocarcinoma clinical trials [3].
Abiraterone, prednisone, and enzalutamide are the most common interventions in prostate adenocarcinoma clinical trials.
Significant Genes in Prostate Adenocarcinoma
ARID1A +
ARID1A is altered in 2.84% of prostate adenocarcinoma patients [2].
ARID1A is an inclusion eligibility criterion in 9 clinical trials for prostate adenocarcinoma, of which 8 are open and 1 is closed. Of the trials that contain ARID1A status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 7 are phase 2 (6 open), and 1 is phase 3 (1 open) [3].
ATM +
ATM is altered in 5.73% of prostate adenocarcinoma patients [2].
ATM is an inclusion eligibility criterion in 20 clinical trials for prostate adenocarcinoma, of which 18 are open and 2 are closed. Of the trials that contain ATM status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 17 are phase 2 (15 open), and 2 are phase 3 (2 open) [3].
ATR +
ATR is altered in 2.14% of prostate adenocarcinoma patients [2].
ATR is an inclusion eligibility criterion in 17 clinical trials for prostate adenocarcinoma, of which 16 are open and 1 is closed. Of the trials that contain ATR status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 14 are phase 2 (13 open), and 2 are phase 3 (2 open) [3].
ATRX +
ATRX is altered in 1.1% of prostate adenocarcinoma patients [2].
ATRX is an inclusion eligibility criterion in 9 clinical trials for prostate adenocarcinoma, of which 8 are open and 1 is closed. Of the trials that contain ATRX status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 7 are phase 2 (6 open), and 1 is phase 3 (1 open) [3].
BARD1 +
BARD1 is altered in 0.67% of prostate adenocarcinoma patients [2].
BARD1 is an inclusion eligibility criterion in 17 clinical trials for prostate adenocarcinoma, of which 16 are open and 1 is closed. Of the trials that contain BARD1 status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 14 are phase 2 (13 open), and 2 are phase 3 (2 open) [3].
BRCA1 +
BRCA1 is altered in 1.22% of prostate adenocarcinoma patients [2].
BRCA1 is an inclusion eligibility criterion in 20 clinical trials for prostate adenocarcinoma, of which 18 are open and 2 are closed. Of the trials that contain BRCA1 status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 17 are phase 2 (15 open), and 2 are phase 3 (2 open) [3].
BRCA2 +
BRCA2 is altered in 6.49% of prostate adenocarcinoma patients [2].
BRCA2 is an inclusion eligibility criterion in 20 clinical trials for prostate adenocarcinoma, of which 18 are open and 2 are closed. Of the trials that contain BRCA2 status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 17 are phase 2 (15 open), and 2 are phase 3 (2 open) [3].
BRIP1 +
BRIP1 is altered in 1.3% of prostate adenocarcinoma patients [2].
BRIP1 is an inclusion eligibility criterion in 18 clinical trials for prostate adenocarcinoma, of which 17 are open and 1 is closed. Of the trials that contain BRIP1 status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 15 are phase 2 (14 open), and 2 are phase 3 (2 open) [3].
C11ORF30 +
C11orf30 is altered in 0.28% of prostate adenocarcinoma patients [2].
C11orf30 is an inclusion eligibility criterion in 9 clinical trials for prostate adenocarcinoma, of which 8 are open and 1 is closed. Of the trials that contain C11orf30 status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 7 are phase 2 (6 open), and 1 is phase 3 (1 open) [3].
CDK12 +
CDK12 is altered in 5.48% of prostate adenocarcinoma patients [2].
CDK12 is an inclusion eligibility criterion in 20 clinical trials for prostate adenocarcinoma, of which 18 are open and 2 are closed. Of the trials that contain CDK12 status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 17 are phase 2 (15 open), and 2 are phase 3 (2 open) [3].
CHEK1 +
CHEK1 is altered in 0.56% of prostate adenocarcinoma patients [2].
CHEK1 is an inclusion eligibility criterion in 17 clinical trials for prostate adenocarcinoma, of which 16 are open and 1 is closed. Of the trials that contain CHEK1 status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 14 are phase 2 (13 open), and 2 are phase 3 (2 open) [3].
CHEK2 +
CHEK2 is altered in 1.04% of prostate adenocarcinoma patients [2].
CHEK2 is an inclusion eligibility criterion in 19 clinical trials for prostate adenocarcinoma, of which 18 are open and 1 is closed. Of the trials that contain CHEK2 status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 16 are phase 2 (15 open), and 2 are phase 3 (2 open) [3].
ERBB2 +
ERBB2 is altered in 1.09% of prostate adenocarcinoma patients [2].
ERBB2 is an inclusion eligibility criterion in 1 clinical trial for prostate adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and prostate adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
ERCC2 +
ERCC2 is altered in 1.06% of prostate adenocarcinoma patients [2].
ERCC2 is an inclusion eligibility criterion in 9 clinical trials for prostate adenocarcinoma, of which 8 are open and 1 is closed. Of the trials that contain ERCC2 status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 7 are phase 2 (6 open), and 1 is phase 3 (1 open) [3].
ERCC3 +
ERCC3 is altered in 0.93% of prostate adenocarcinoma patients [2].
ERCC3 is an inclusion eligibility criterion in 10 clinical trials for prostate adenocarcinoma, of which 9 are open and 1 is closed. Of the trials that contain ERCC3 status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 8 are phase 2 (7 open), and 1 is phase 3 (1 open) [3].
ERCC4 +
ERCC4 is altered in 0.75% of prostate adenocarcinoma patients [2].
ERCC4 is an inclusion eligibility criterion in 9 clinical trials for prostate adenocarcinoma, of which 8 are open and 1 is closed. Of the trials that contain ERCC4 status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 7 are phase 2 (6 open), and 1 is phase 3 (1 open) [3].
ERCC5 +
ERCC5 is altered in 1.64% of prostate adenocarcinoma patients [2].
ERCC5 is an inclusion eligibility criterion in 9 clinical trials for prostate adenocarcinoma, of which 8 are open and 1 is closed. Of the trials that contain ERCC5 status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 7 are phase 2 (6 open), and 1 is phase 3 (1 open) [3].
ERCC6 +
ERCC6 is altered in 0.45% of prostate adenocarcinoma patients [2].
ERCC6 is an inclusion eligibility criterion in 9 clinical trials for prostate adenocarcinoma, of which 8 are open and 1 is closed. Of the trials that contain ERCC6 status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 7 are phase 2 (6 open), and 1 is phase 3 (1 open) [3].
FAM175A +
FAM175A is altered in 0.54% of prostate adenocarcinoma patients [2].
FAM175A is an inclusion eligibility criterion in 1 clinical trial for prostate adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FAM175A status and prostate adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
FANCA +
FANCA is altered in 2.71% of prostate adenocarcinoma patients [2].
FANCA is an inclusion eligibility criterion in 20 clinical trials for prostate adenocarcinoma, of which 18 are open and 2 are closed. Of the trials that contain FANCA status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 17 are phase 2 (15 open), and 2 are phase 3 (2 open) [3].
FANCB +
FANCB is altered in 0.4% of prostate adenocarcinoma patients [2].
FANCB is an inclusion eligibility criterion in 18 clinical trials for prostate adenocarcinoma, of which 17 are open and 1 is closed. Of the trials that contain FANCB status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 15 are phase 2 (14 open), and 2 are phase 3 (2 open) [3].
FANCC +
FANCC is altered in 0.86% of prostate adenocarcinoma patients [2].
FANCC is an inclusion eligibility criterion in 18 clinical trials for prostate adenocarcinoma, of which 17 are open and 1 is closed. Of the trials that contain FANCC status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 15 are phase 2 (14 open), and 2 are phase 3 (2 open) [3].
FANCD2 +
FANCD2 is altered in 1.87% of prostate adenocarcinoma patients [2].
FANCD2 is an inclusion eligibility criterion in 18 clinical trials for prostate adenocarcinoma, of which 17 are open and 1 is closed. Of the trials that contain FANCD2 status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 15 are phase 2 (14 open), and 2 are phase 3 (2 open) [3].
FANCE +
FANCE is altered in 0.51% of prostate adenocarcinoma patients [2].
FANCE is an inclusion eligibility criterion in 18 clinical trials for prostate adenocarcinoma, of which 17 are open and 1 is closed. Of the trials that contain FANCE status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 15 are phase 2 (14 open), and 2 are phase 3 (2 open) [3].
FANCF +
FANCF is altered in 0.75% of prostate adenocarcinoma patients [2].
FANCF is an inclusion eligibility criterion in 18 clinical trials for prostate adenocarcinoma, of which 17 are open and 1 is closed. Of the trials that contain FANCF status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 15 are phase 2 (14 open), and 2 are phase 3 (2 open) [3].
FANCG +
FANCG is altered in 1.47% of prostate adenocarcinoma patients [2].
FANCG is an inclusion eligibility criterion in 18 clinical trials for prostate adenocarcinoma, of which 17 are open and 1 is closed. Of the trials that contain FANCG status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 15 are phase 2 (14 open), and 2 are phase 3 (2 open) [3].
FANCI +
FANCI is altered in 3.33% of prostate adenocarcinoma patients [2].
FANCI is an inclusion eligibility criterion in 18 clinical trials for prostate adenocarcinoma, of which 17 are open and 1 is closed. Of the trials that contain FANCI status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 15 are phase 2 (14 open), and 2 are phase 3 (2 open) [3].
FANCL +
FANCL is altered in 1.01% of prostate adenocarcinoma patients [2].
FANCL is an inclusion eligibility criterion in 18 clinical trials for prostate adenocarcinoma, of which 17 are open and 1 is closed. Of the trials that contain FANCL status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 15 are phase 2 (14 open), and 2 are phase 3 (2 open) [3].
FANCM +
FANCM is altered in 3.57% of prostate adenocarcinoma patients [2].
FANCM is an inclusion eligibility criterion in 18 clinical trials for prostate adenocarcinoma, of which 17 are open and 1 is closed. Of the trials that contain FANCM status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 15 are phase 2 (14 open), and 2 are phase 3 (2 open) [3].
GEN1 +
GEN1 is altered in 1.57% of prostate adenocarcinoma patients [2].
GEN1 is an inclusion eligibility criterion in 2 clinical trials for prostate adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain GEN1 status and prostate adenocarcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].
HDAC1 +
HDAC1 is an inclusion eligibility criterion in 9 clinical trials for prostate adenocarcinoma, of which 8 are open and 1 is closed. Of the trials that contain HDAC1 status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 7 are phase 2 (6 open), and 1 is phase 3 (1 open) [3].
HDAC2 +
HDAC2 is an inclusion eligibility criterion in 11 clinical trials for prostate adenocarcinoma, of which 10 are open and 1 is closed. Of the trials that contain HDAC2 status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 9 are phase 2 (8 open), and 1 is phase 3 (1 open) [3].
MCPH1 +
MCPH1 is an inclusion eligibility criterion in 8 clinical trials for prostate adenocarcinoma, of which 8 are open and 0 are closed. Of the trials that contain MCPH1 status and prostate adenocarcinoma as inclusion criteria, 7 are phase 2 (7 open) and 1 is phase 3 (1 open) [3].
MDM2 +
MDM2 is altered in 0.78% of prostate adenocarcinoma patients [2].
MDM2 is an inclusion eligibility criterion in 9 clinical trials for prostate adenocarcinoma, of which 8 are open and 1 is closed. Of the trials that contain MDM2 status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 7 are phase 2 (6 open), and 1 is phase 3 (1 open) [3].
MDM4 +
MDM4 is altered in 1.24% of prostate adenocarcinoma patients [2].
MDM4 is an inclusion eligibility criterion in 9 clinical trials for prostate adenocarcinoma, of which 8 are open and 1 is closed. Of the trials that contain MDM4 status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 7 are phase 2 (6 open), and 1 is phase 3 (1 open) [3].
MLF1 +
MLF1 is an inclusion eligibility criterion in 9 clinical trials for prostate adenocarcinoma, of which 8 are open and 1 is closed. Of the trials that contain MLF1 status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 7 are phase 2 (6 open), and 1 is phase 3 (1 open) [3].
MLH1 +
MLH1 is altered in 0.87% of prostate adenocarcinoma patients [2].
MLH1 is an inclusion eligibility criterion in 12 clinical trials for prostate adenocarcinoma, of which 11 are open and 1 is closed. Of the trials that contain MLH1 status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 10 are phase 2 (9 open), and 1 is phase 3 (1 open) [3].
MLH3 +
MLH3 is altered in 2.87% of prostate adenocarcinoma patients [2].
MLH3 is an inclusion eligibility criterion in 11 clinical trials for prostate adenocarcinoma, of which 10 are open and 1 is closed. Of the trials that contain MLH3 status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 9 are phase 2 (8 open), and 1 is phase 3 (1 open) [3].
MRE11A +
MRE11A is altered in 0.97% of prostate adenocarcinoma patients [2].
MRE11A is an inclusion eligibility criterion in 18 clinical trials for prostate adenocarcinoma, of which 17 are open and 1 is closed. Of the trials that contain MRE11A status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 15 are phase 2 (14 open), and 2 are phase 3 (2 open) [3].
MSH2 +
MSH2 is altered in 1.88% of prostate adenocarcinoma patients [2].
MSH2 is an inclusion eligibility criterion in 11 clinical trials for prostate adenocarcinoma, of which 10 are open and 1 is closed. Of the trials that contain MSH2 status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 9 are phase 2 (8 open), and 1 is phase 3 (1 open) [3].
MSH3 +
MSH3 is altered in 2.13% of prostate adenocarcinoma patients [2].
MSH3 is an inclusion eligibility criterion in 10 clinical trials for prostate adenocarcinoma, of which 9 are open and 1 is closed. Of the trials that contain MSH3 status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 8 are phase 2 (7 open), and 1 is phase 3 (1 open) [3].
MSH6 +
MSH6 is altered in 1.99% of prostate adenocarcinoma patients [2].
MSH6 is an inclusion eligibility criterion in 11 clinical trials for prostate adenocarcinoma, of which 10 are open and 1 is closed. Of the trials that contain MSH6 status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 9 are phase 2 (8 open), and 1 is phase 3 (1 open) [3].
MUTYH +
MUTYH is altered in 0.7% of prostate adenocarcinoma patients [2].
MUTYH is an inclusion eligibility criterion in 9 clinical trials for prostate adenocarcinoma, of which 8 are open and 1 is closed. Of the trials that contain MUTYH status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 7 are phase 2 (6 open), and 1 is phase 3 (1 open) [3].
NBN +
NBN is altered in 3.31% of prostate adenocarcinoma patients [2].
NBN is an inclusion eligibility criterion in 18 clinical trials for prostate adenocarcinoma, of which 17 are open and 1 is closed. Of the trials that contain NBN status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 15 are phase 2 (14 open), and 2 are phase 3 (2 open) [3].
NPM1 +
NPM1 is altered in 0.31% of prostate adenocarcinoma patients [2].
NPM1 is an inclusion eligibility criterion in 9 clinical trials for prostate adenocarcinoma, of which 8 are open and 1 is closed. Of the trials that contain NPM1 status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 7 are phase 2 (6 open), and 1 is phase 3 (1 open) [3].
PALB2 +
PALB2 is altered in 1.43% of prostate adenocarcinoma patients [2].
PALB2 is an inclusion eligibility criterion in 20 clinical trials for prostate adenocarcinoma, of which 18 are open and 2 are closed. Of the trials that contain PALB2 status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 17 are phase 2 (15 open), and 2 are phase 3 (2 open) [3].
PARP1 +
PARP1 is altered in 0.92% of prostate adenocarcinoma patients [2].
PARP1 is an inclusion eligibility criterion in 9 clinical trials for prostate adenocarcinoma, of which 8 are open and 1 is closed. Of the trials that contain PARP1 status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 7 are phase 2 (6 open), and 1 is phase 3 (1 open) [3].
PARP2 +
PARP2 is altered in 5.26% of prostate adenocarcinoma patients [2].
PARP2 is an inclusion eligibility criterion in 9 clinical trials for prostate adenocarcinoma, of which 8 are open and 1 is closed. Of the trials that contain PARP2 status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 7 are phase 2 (6 open), and 1 is phase 3 (1 open) [3].
PMS1 +
PMS1 is altered in 0.67% of prostate adenocarcinoma patients [2].
PMS1 is an inclusion eligibility criterion in 11 clinical trials for prostate adenocarcinoma, of which 10 are open and 1 is closed. Of the trials that contain PMS1 status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 9 are phase 2 (8 open), and 1 is phase 3 (1 open) [3].
PMS2 +
PMS2 is altered in 1.28% of prostate adenocarcinoma patients [2].
PMS2 is an inclusion eligibility criterion in 11 clinical trials for prostate adenocarcinoma, of which 10 are open and 1 is closed. Of the trials that contain PMS2 status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 9 are phase 2 (8 open), and 1 is phase 3 (1 open) [3].
POLE +
POLE is altered in 2.42% of prostate adenocarcinoma patients [2].
POLE is an inclusion eligibility criterion in 9 clinical trials for prostate adenocarcinoma, of which 8 are open and 1 is closed. Of the trials that contain POLE status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 7 are phase 2 (6 open), and 1 is phase 3 (1 open) [3].
PPP2R1A +
PPP2R1A is altered in 0.97% of prostate adenocarcinoma patients [2].
PPP2R1A is an inclusion eligibility criterion in 9 clinical trials for prostate adenocarcinoma, of which 8 are open and 1 is closed. Of the trials that contain PPP2R1A status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 7 are phase 2 (6 open), and 1 is phase 3 (1 open) [3].
PPP2R2A +
PPP2R2A is an inclusion eligibility criterion in 10 clinical trials for prostate adenocarcinoma, of which 9 are open and 1 is closed. Of the trials that contain PPP2R2A status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 8 are phase 2 (7 open), and 1 is phase 3 (1 open) [3].
PTEN +
PTEN is altered in 17.72% of prostate adenocarcinoma patients [2].
PTEN is an inclusion eligibility criterion in 10 clinical trials for prostate adenocarcinoma, of which 9 are open and 1 is closed. Of the trials that contain PTEN status and prostate adenocarcinoma as inclusion criteria, 9 are phase 2 (8 open) and 1 is phase 3 (1 open) [3].
RAD50 +
RAD50 is altered in 0.73% of prostate adenocarcinoma patients [2].
RAD50 is an inclusion eligibility criterion in 18 clinical trials for prostate adenocarcinoma, of which 17 are open and 1 is closed. Of the trials that contain RAD50 status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 15 are phase 2 (14 open), and 2 are phase 3 (2 open) [3].
RAD51 +
RAD51 is altered in 0.22% of prostate adenocarcinoma patients [2].
RAD51 is an inclusion eligibility criterion in 17 clinical trials for prostate adenocarcinoma, of which 16 are open and 1 is closed. Of the trials that contain RAD51 status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 14 are phase 2 (13 open), and 2 are phase 3 (2 open) [3].
RAD51B +
RAD51B is altered in 0.47% of prostate adenocarcinoma patients [2].
RAD51B is an inclusion eligibility criterion in 17 clinical trials for prostate adenocarcinoma, of which 16 are open and 1 is closed. Of the trials that contain RAD51B status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 14 are phase 2 (13 open), and 2 are phase 3 (2 open) [3].
RAD51C +
RAD51C is altered in 0.55% of prostate adenocarcinoma patients [2].
RAD51C is an inclusion eligibility criterion in 18 clinical trials for prostate adenocarcinoma, of which 17 are open and 1 is closed. Of the trials that contain RAD51C status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 15 are phase 2 (14 open), and 2 are phase 3 (2 open) [3].
RAD51D +
RAD51D is altered in 0.18% of prostate adenocarcinoma patients [2].
RAD51D is an inclusion eligibility criterion in 18 clinical trials for prostate adenocarcinoma, of which 17 are open and 1 is closed. Of the trials that contain RAD51D status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 15 are phase 2 (14 open), and 2 are phase 3 (2 open) [3].
RAD54L +
RAD54L is altered in 0.51% of prostate adenocarcinoma patients [2].
RAD54L is an inclusion eligibility criterion in 17 clinical trials for prostate adenocarcinoma, of which 16 are open and 1 is closed. Of the trials that contain RAD54L status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 14 are phase 2 (13 open), and 2 are phase 3 (2 open) [3].
RB1 +
RB1 is altered in 5.19% of prostate adenocarcinoma patients [2].
RB1 is an inclusion eligibility criterion in 2 clinical trials for prostate adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain RB1 status and prostate adenocarcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].
SLX4 +
SLX4 is altered in 2.54% of prostate adenocarcinoma patients [2].
SLX4 is an inclusion eligibility criterion in 17 clinical trials for prostate adenocarcinoma, of which 16 are open and 1 is closed. Of the trials that contain SLX4 status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 14 are phase 2 (13 open), and 2 are phase 3 (2 open) [3].
SMARCB1 +
SMARCB1 is altered in 0.57% of prostate adenocarcinoma patients [2].
SMARCB1 is an inclusion eligibility criterion in 9 clinical trials for prostate adenocarcinoma, of which 8 are open and 1 is closed. Of the trials that contain SMARCB1 status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 7 are phase 2 (6 open), and 1 is phase 3 (1 open) [3].
STAG2 +
STAG2 is altered in 1.11% of prostate adenocarcinoma patients [2].
STAG2 is an inclusion eligibility criterion in 9 clinical trials for prostate adenocarcinoma, of which 8 are open and 1 is closed. Of the trials that contain STAG2 status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 7 are phase 2 (6 open), and 1 is phase 3 (1 open) [3].
STK11 +
STK11 is altered in 0.59% of prostate adenocarcinoma patients [2].
STK11 is an inclusion eligibility criterion in 9 clinical trials for prostate adenocarcinoma, of which 8 are open and 1 is closed. Of the trials that contain STK11 status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 7 are phase 2 (6 open), and 1 is phase 3 (1 open) [3].
TP53 +
TP53 is altered in 28.47% of prostate adenocarcinoma patients [2].
TP53 is an inclusion eligibility criterion in 1 clinical trial for prostate adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains TP53 status and prostate adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
XRCC1 +
XRCC1 is altered in 0.79% of prostate adenocarcinoma patients [2].
XRCC1 is an inclusion eligibility criterion in 9 clinical trials for prostate adenocarcinoma, of which 8 are open and 1 is closed. Of the trials that contain XRCC1 status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 7 are phase 2 (6 open), and 1 is phase 3 (1 open) [3].
Disease Details
References
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.
